Codexis, Inc. Stock price

Equities

CDXS

US1920051067

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
3.49 USD -0.57% Intraday chart for Codexis, Inc. 0.00% +14.43%
Sales 2024 * 65.38M Sales 2025 * 62.05M Capitalization 245M
Net income 2024 * -46M Net income 2025 * -49M EV / Sales 2024 * 3.75 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 3.95 x
P/E ratio 2024 *
-5.4 x
P/E ratio 2025 *
-5.11 x
Employees 174
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.78%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.57%
Current month-24.95%
1 month-6.18%
3 months+11.50%
6 months+105.29%
Current year+14.43%
More quotes
1 week
3.41
Extreme 3.405
3.72
1 month
3.04
Extreme 3.035
4.71
Current year
2.53
Extreme 2.53
4.91
1 year
1.45
Extreme 1.45
4.91
3 years
1.45
Extreme 1.45
42.01
5 years
1.45
Extreme 1.45
42.01
10 years
1.34
Extreme 1.34
42.01
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 20-06-15
Director of Finance/CFO 43 23-01-22
Compliance Officer 53 22-10-31
Members of the board TitleAgeSince
Director/Board Member 64 16-02-29
Director/Board Member 59 22-09-27
Chief Executive Officer 64 20-06-15
More insiders
Date Price Change Volume
24-03-28 3.49 -0.57% 447,898
24-03-27 3.51 +1.74% 497,241
24-03-26 3.45 0.00% 337,252
24-03-25 3.45 0.00% 350,116
24-03-22 3.45 -1.15% 331,753

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.49 USD
Average target price
6.571 USD
Spread / Average Target
+88.29%
Consensus
  1. Stock
  2. Equities
  3. Stock Codexis, Inc. - Nasdaq